Nature Reviews Cardiology最新文献_第3页

Interferon response at the border zone of the infarcted heart 梗死心脏边界区的干扰素反应

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-17 DOI: 10.1038/s41569-024-01078-y

Karina Huynh

引用次数: 0

Differential roles of eosinophils in cardiovascular disease 嗜酸性粒细胞在心血管疾病中的不同作用

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-16 DOI: 10.1038/s41569-024-01071-5

Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi

{"title":"Differential roles of eosinophils in cardiovascular disease","authors":"Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi","doi":"10.1038/s41569-024-01071-5","DOIUrl":"https://doi.org/10.1038/s41569-024-01071-5","url":null,"abstract":"Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":49.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atheroimmunology: keeping the immune system in atherosclerosis in check 动脉粥样硬化免疫学：控制动脉粥样硬化的免疫系统

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-09-11 DOI: 10.1038/s41569-024-01075-1

Claudia Monaco, Lea Dib

引用次数: 0

Pathophysiological insights into HFpEF from studies of human cardiac tissue 从人体心脏组织研究中了解高频心衰的病理生理学原理

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-28 DOI: 10.1038/s41569-024-01067-1

Ahmed U. Fayyaz, Muhammad Eltony, Larry J. Prokop, Katlyn E. Koepp, Barry A. Borlaug, Surendra Dasari, Melanie C. Bois, Kenneth B. Margulies, Joesph J. Maleszewski, Ying Wang, Margaret M. Redfield

{"title":"Pathophysiological insights into HFpEF from studies of human cardiac tissue","authors":"Ahmed U. Fayyaz, Muhammad Eltony, Larry J. Prokop, Katlyn E. Koepp, Barry A. Borlaug, Surendra Dasari, Melanie C. Bois, Kenneth B. Margulies, Joesph J. Maleszewski, Ying Wang, Margaret M. Redfield","doi":"10.1038/s41569-024-01067-1","DOIUrl":"https://doi.org/10.1038/s41569-024-01067-1","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is a major, worldwide health-care problem. Few therapies for HFpEF exist because the pathophysiology of this condition is poorly defined and, increasingly, postulated to be diverse. Although perturbations in other organs contribute to the clinical profile in HFpEF, altered cardiac structure, function or both are the primary causes of this heart failure syndrome. Therefore, studying myocardial tissue is fundamental to improve pathophysiological insights and therapeutic discovery in HFpEF. Most studies of myocardial changes in HFpEF have relied on cardiac tissue from animal models without (or with limited) confirmatory studies in human cardiac tissue. Animal models of HFpEF have evolved based on theoretical HFpEF aetiologies, but these models might not reflect the complex pathophysiology of human HFpEF. The focus of this Review is the pathophysiological insights gained from studies of human HFpEF myocardium. We outline the rationale for these studies, the challenges and opportunities in obtaining myocardial tissue from patients with HFpEF and relevant comparator groups, the analytical approaches, the pathophysiological insights gained to date and the remaining knowledge gaps. Our objective is to provide a roadmap for future studies of cardiac tissue from diverse cohorts of patients with HFpEF, coupling discovery biology with measures to account for pathophysiological diversity.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":49.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142085620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms and treatment of pulmonary arterial hypertension 肺动脉高压的机制和治疗

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-07 DOI: 10.1038/s41569-024-01064-4

Hossein-Ardeschir Ghofrani, Mardi Gomberg-Maitland, Lan Zhao, Friedrich Grimminger

{"title":"Mechanisms and treatment of pulmonary arterial hypertension","authors":"Hossein-Ardeschir Ghofrani, Mardi Gomberg-Maitland, Lan Zhao, Friedrich Grimminger","doi":"10.1038/s41569-024-01064-4","DOIUrl":"https://doi.org/10.1038/s41569-024-01064-4","url":null,"abstract":"Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":49.6,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stroke triggers an innate immune memory that drives cardiac dysfunction 中风引发先天性免疫记忆，导致心脏功能障碍

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-08-07 DOI: 10.1038/s41569-024-01069-z

Irene Fernández-Ruiz

引用次数: 0

Potential new therapeutic target for HFpEF 高频心衰的潜在新治疗靶点。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-07-29 DOI: 10.1038/s41569-024-01066-2

Irene Fernández-Ruiz

引用次数: 0

Epidemiology of cardiometabolic health in Latin America and strategies to address disparities. 拉丁美洲心脏代谢健康的流行病学和消除差异的战略。

IF 41.7 1区医学

Nature Reviews Cardiology Pub Date : 2024-07-25 DOI: 10.1038/s41569-024-01058-2

Luisa C C Brant, J Jaime Miranda, Rodrigo M Carrillo-Larco, David Flood, Vilma Irazola, Antonio Luiz P Ribeiro

{"title":"Epidemiology of cardiometabolic health in Latin America and strategies to address disparities.","authors":"Luisa C C Brant, J Jaime Miranda, Rodrigo M Carrillo-Larco, David Flood, Vilma Irazola, Antonio Luiz P Ribeiro","doi":"10.1038/s41569-024-01058-2","DOIUrl":"https://doi.org/10.1038/s41569-024-01058-2","url":null,"abstract":"In Latin America and the Caribbean (LAC), sociodemographic context, socioeconomic disparities and the high level of urbanization provide a unique entry point to reflect on the burden of cardiometabolic disease in the region. Cardiovascular diseases are the main cause of death in LAC, precipitated by population growth and ageing together with a rapid increase in the prevalence of cardiometabolic risk factors, predominantly obesity and diabetes mellitus, over the past four decades. Strategies to address this growing cardiometabolic burden include both population-wide and individual-based initiatives tailored to the specific challenges faced by different LAC countries, which are heterogeneous. The implementation of public policies to reduce smoking and health system approaches to control hypertension are examples of scalable strategies. The challenges faced by LAC are also opportunities to foster innovative approaches to combat the high burden of cardiometabolic diseases such as implementing digital health interventions and team-based initiatives. This Review provides a summary of trends in the epidemiology of cardiometabolic diseases and their risk factors in LAC as well as context-specific disease determinants and potential solutions to improve cardiometabolic health in the region.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":41.7,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reactive oxygen species in hypertension 高血压中的活性氧

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-07-24 DOI: 10.1038/s41569-024-01062-6

Livia L. Camargo, Francisco J. Rios, Augusto C. Montezano, Rhian M. Touyz

{"title":"Reactive oxygen species in hypertension","authors":"Livia L. Camargo, Francisco J. Rios, Augusto C. Montezano, Rhian M. Touyz","doi":"10.1038/s41569-024-01062-6","DOIUrl":"https://doi.org/10.1038/s41569-024-01062-6","url":null,"abstract":"Hypertension is a leading risk factor for stroke, heart disease and chronic kidney disease. Multiple interacting factors and organ systems increase blood pressure and cause target-organ damage. Among the many molecular elements involved in the development of hypertension are reactive oxygen species (ROS), which influence cellular processes in systems that contribute to blood pressure elevation (such as the cardiovascular, renal, immune and central nervous systems, or the renin–angiotensin–aldosterone system). Dysregulated ROS production (oxidative stress) is a hallmark of hypertension in humans and experimental models. Of the many ROS-generating enzymes, NADPH oxidases are the most important in the development of hypertension. At the cellular level, ROS influence signalling pathways that define cell fate and function. Oxidative stress promotes aberrant redox signalling and cell injury, causing endothelial dysfunction, vascular damage, cardiovascular remodelling, inflammation and renal injury, which are all important in both the causes and consequences of hypertension. ROS scavengers reduce blood pressure in almost all experimental models of hypertension; however, clinical trials of antioxidants have yielded mixed results. In this Review, we highlight the latest advances in the understanding of the role and the clinical implications of ROS in hypertension. We focus on cellular sources of ROS, molecular mechanisms of oxidative stress and alterations in redox signalling in organ systems, and their contributions to hypertension.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":49.6,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141754745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop 心血管疾病视网膜成像生物标志物的标准化和临床应用：国家卫生和生物技术研究所研讨会路线图

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2024-07-22 DOI: 10.1038/s41569-024-01060-8

Emily Y. Chew, Stephen A. Burns, Alison G. Abraham, Mathieu F. Bakhoum, Joshua A. Beckman, Toco Y. P. Chui, Robert P. Finger, Alejandro F. Frangi, Rebecca F. Gottesman, Maria B. Grant, Henner Hanssen, Cecilia S. Lee, Michelle L. Meyer, Damiano Rizzoni, Alicja R. Rudnicka, Joel S. Schuman, Sara B. Seidelmann, W. H. Wilson Tang, Bishow B. Adhikari, Narasimhan Danthi, Yuling Hong, Diane Reid, Grace L. Shen, Young S. Oh

{"title":"Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop","authors":"Emily Y. Chew, Stephen A. Burns, Alison G. Abraham, Mathieu F. Bakhoum, Joshua A. Beckman, Toco Y. P. Chui, Robert P. Finger, Alejandro F. Frangi, Rebecca F. Gottesman, Maria B. Grant, Henner Hanssen, Cecilia S. Lee, Michelle L. Meyer, Damiano Rizzoni, Alicja R. Rudnicka, Joel S. Schuman, Sara B. Seidelmann, W. H. Wilson Tang, Bishow B. Adhikari, Narasimhan Danthi, Yuling Hong, Diane Reid, Grace L. Shen, Young S. Oh","doi":"10.1038/s41569-024-01060-8","DOIUrl":"https://doi.org/10.1038/s41569-024-01060-8","url":null,"abstract":"The accessibility of the retina with the use of non-invasive and relatively low-cost ophthalmic imaging techniques and analytics provides a unique opportunity to improve the detection, diagnosis and monitoring of systemic diseases. The National Heart, Lung, and Blood Institute conducted a workshop in October 2022 to examine this concept. On the basis of the discussions at that workshop, this Roadmap describes current knowledge gaps and new research opportunities to evaluate the relationships between the eye (in particular, retinal biomarkers) and the risk of cardiovascular diseases, including coronary artery disease, heart failure, stroke, hypertension and vascular dementia. Identified gaps include the need to simplify and standardize the capture of high-quality images of the eye by non-ophthalmic health workers and to conduct longitudinal studies using multidisciplinary networks of diverse at-risk populations with improved implementation and methods to protect participant and dataset privacy. Other gaps include improving the measurement of structural and functional retinal biomarkers, determining the relationship between microvascular and macrovascular risk factors, improving multimodal imaging ‘pipelines’, and integrating advanced imaging with ‘omics’, lifestyle factors, primary care data and radiological reports, by using artificial intelligence technology to improve the identification of individual-level risk. Future research on retinal microvascular disease and retinal biomarkers might additionally provide insights into the temporal development of microvascular disease across other systemic vascular beds.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":null,"pages":null},"PeriodicalIF":49.6,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0